Abstract
目的探讨结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者的临床病理特征及疗效。方法收集14例NLPHL患者的临床资料,对其临床病理特征及近、远期疗效进行相关性分析。结果14例患者均为初治者,男、女各7例,中位发病年龄38(13~54)岁,中位随访时间为55.5(23~189)个月。发病率占同期霍奇金淋巴瘤(HL)的6.3%(14/223)。免疫组织化学检查结果示14例患者CD20均呈(+)/弱(+),CD30均(−),仅1例患者呈CD15弱(+)。14例患者中13例因自觉浅表淋巴结肿大就诊,所有患者惰性起病,病情进展缓慢。7例患者采用单纯化疗,7例患者采用放、化疗联合治疗。14例患者均有效,其中完全缓解(CR)+未证实的CR(CRu)12例。5年无疾病生存率为85.7%,5年总生存率为100.0%。单纯化疗与放、化疗联合治疗相比,不同的化疗方案相比,其近、远期疗效差异均无统计学意义(P值均>0.05)。结论NLPHL患者瘤细胞呈CD20(+)/弱(+),CD30(−),极少数患者呈CD15弱(+)。NLPHL在HL患者中所占比例低,以中青年患者多见,起病缓慢,与经典型HL患者相比疗效较好。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.